GH56
Oncology (specific tumors not specified)
Phase 1Active (investigator meeting held August 2025)
Key Facts
Indication
Oncology (specific tumors not specified)
Phase
Phase 1
Status
Active (investigator meeting held August 2025)
Company
About Genhouse Bio
Chinese biotech developing targeted oncology therapies focused on Ras-MAPK pathway and synthetic lethality mechanisms.
View full company profileTherapeutic Areas
Other Oncology (specific tumors not specified) Drugs
| Drug | Company | Phase |
|---|---|---|
| GH31 | Genhouse Bio | Phase 1 |